Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.64 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.53 |
| ▸ | CASP2 | P42575 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27586328 | 1.00 | FAAH (0.64) | FAAHHSP90AA1DNM1CASP2MEN1 | |
| SCHEMBL13241883 | 1.00 | FAAH (0.64) | FAAHHSP90AA1DNM1CASP2MEN1 | |
| SCHEMBL18023468 | 1.00 | FAAH (0.64) | FAAHHSP90AA1DNM1CASP2MEN1 | |
| SCHEMBL13241886 | 1.00 | FAAH (0.64) | FAAHHSP90AA1DNM1CASP2MEN1 | |
| SCHEMBL14071552 | 1.00 | FAAH (0.64) | FAAHHSP90AA1DNM1CASP2MEN1 | |
| SCHEMBL4849009 | 0.98 | FAAH (0.61) | FAAHHSP90AA1DNM1CASP2MEN1 | |
| SCHEMBL22746115 | 0.92 | FAAH (0.52) | FAAHHSP90AA1DNM1CASP2NAAA | |
| SCHEMBL11505724 | 0.89 | RECQL (0.58) | FAAHHSP90AA1DNM1MEN1KMT2A | |
| SCHEMBL17049333 | 0.83 | — | — | |
| SCHEMBL6652097 | 0.81 | CNR1 (0.68) | FAAHHSP90AA1DNM1CASP2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3285771-A1 | METHODS OF TREATING PARKINSON'S DISEASE BY ADMINISTRATION OF APOMORPHINE TO AN ORAL MUCOSA | Sunovion Pharmaceuticals Inc. (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016172095-A1 | METHODS OF TREATING PARKINSON'S DISEASE BY ADMINISTRATION OF APOMORPHINE TO AN ORAL MUCOSA | CYNAPSUS THERAPEUTICS, INC. (CA) | 2016-10-27 | — | — | WO | disclosed |
| EP-2442650-A1 | SUBLINGUAL APOMORPHINE | Adagio Pharmaceuticals Inc. (CA) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010144817-A1 | SUBLINGUAL APOMORPHINE | ADAGIO PHARMACEUTICALS LTD. (CA) | 2010-12-16 | — | — | WO | disclosed |